Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.65 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.65 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058865 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL335652 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL2123406 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6339022 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL23410453 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL13518560 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL16212072 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356559 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL1008776 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13050975 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | claimed |
| CN-114249735-A | PARP inhibitor intermediate crystal form and preparation method and application thereof | 江西青峰药业有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-03 | — | — | US | claimed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | claimed |
| WO-2025052649-A1 | METHOD FOR SELECTIVE PRODUCTION OF SINGLE AXIALLY CHIRAL COMPOUND | アステラス製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240208956-A1 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CHRNB2 4631/4885CHRNA4 4823/4885CHRNA3 4753/4885 |
| US-20210163456-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | CHRNB2 4077/4885CHRNA4 4660/4885CHRNA3 4387/4885 |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | CHRNB2 354/4885CHRNA4 147/4885CHRNA3 100/4885 |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | HYOU1, CHN2, PURB | CHRNB2 677/4885CHRNA4 1338/4885CHRNA3 1119/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | CHRNB2 4132/4885CHRNA4 3117/4885CHRNA3 3571/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CHRNB2 4832/4885CHRNA4 4756/4885CHRNA3 4571/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | CHRNB2 4502/4885CHRNA4 4670/4885CHRNA3 4580/4885 |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | ALK, ABL2, ACVR2A | CHRNB2 742/4885CHRNA4 1586/4885CHRNA3 1770/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | CHRNB2 4796/4885CHRNA4 4781/4885CHRNA3 4655/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | CHRNB2 621/4885CHRNA4 572/4885CHRNA3 535/4885 |
| US-20240208956-A1 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC11 | CHRNB2 3664/4885CHRNA4 2863/4885CHRNA3 2234/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | CHRNB2 4796/4885CHRNA4 4781/4885CHRNA3 4655/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | CHRNB2 2827/4885CHRNA4 3154/4885CHRNA3 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.